A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

Part of paid clinical trials in Los Angeles, California.

Sponsor
Dasher Neuroscience Inc.
Study ID
NCT06848231
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Multiple System Atrophy

Eligibility Criteria

Sex
ALL
Age
30 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • YA-101 — DRUG
    Drug: YA-101 • YA-101 taken BID
  • Placebo — DRUG
    Placebo taken BID

Study Details

This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.

Key Dates

Start date
Mar 3, 2025
Status verified
Jun 2025
Primary completion
Jun 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
75 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: YA-101
  • Placebo Comparator: Placebo

Primary Outcome Measure

Incidence and severity of Adverse Events (AEs) [ Time Frame: Baseline to Day 112 ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
UCLA HealthLos AngelesCalifornia90095
Westley Ulit
310-206-8153
Brigham and Women's HospitalBostonMassachusetts02115
Anya Gemos
[email protected]
510-755-3948
Mayo ClinicRochesterMinnesota55905-
Columbia University Irving medical centerNew YorkNew York10032
Nadia Amokrane
347-882-4315
Vanderbilt University Medical CenterNashvilleTennessee37232
Maeve Curtin
[email protected]
Baylor College of MedicineHoustonTexas77030
Rory Mahabir
[email protected]
713-798-5989

Find similar trials in Los Angeles, CA

By research site
UCLA Health· Los Angeles, CABrigham and Women's Hospital· Boston, MAMayo Clinic· Rochester, MNColumbia University Irving medical center· New York, NYVanderbilt University Medical Center· Nashville, TNBaylor College of Medicine· Houston, TX

Related Studies